Fosinopril sodium is a white to off-white crystalline powder, soluble (>100 mg/mL) in water, in ethanol, and in methanol, and slightly soluble in hexane.
Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension.
These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION.)
In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).
ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema.)
Media Articles Related to Fosinopril and Hydrochlorothiazide (Fosinopril / Hydrochlorothiazide)
Diet Effects Debated in Intracranial Hypertension
Source: Medscape Ophthalmology Headlines [2015.02.27]
Does acetazolamide improve symptoms of intracranial hypertension by lowering cerebrospinal fluid pressure, or does it work by increasing weight loss?
Medscape Medical News
Source: MedicineNet Fainting Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM
"Danger" molecule may be new therapeutic target for male hypertension
Source: Hypertension News From Medical News Today [2015.02.17]
Higher levels of a "danger" molecule may be one reason males tend to become hypertensive earlier and more severely than females, scientists say.
Pregnancy associated hypertension linked to an increased frequency of subsequent hypertension and metabolic syndrome
Source: Hypertension News From Medical News Today [2015.02.04]
In a study to be presented on Feb. 5 in an oral concurrent session at 2:45 p.m.
New hypertension guidelines could save lives and money
Source: Hypertension News From Medical News Today [2015.01.30]
Increased treatment of severe hypertension particularly cost-effectiveFull implementation of new hypertension guidelines could prevent 56,000 cardiovascular disease events (mostly heart attacks...
Published Studies Related to Fosinopril and Hydrochlorothiazide (Fosinopril / Hydrochlorothiazide)
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. [2004.12]
BACKGROUND AND PURPOSE: The Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS) tested whether (1) the angiotensin-converting enzyme (ACE) inhibitor fosinopril (20 mg per day) was more effective on carotid atherosclerosis progression than the diuretic hydrochlorothiazide (25 mg per day), (2) pravastatin (40 mg per day) was more effective than placebo when added to either hydrochlorothiazide or fosinopril, and (3) there were additive effects of ACE inhibitor and lipid-lowering therapies... CONCLUSIONS: Progression of carotid atherosclerosis occurred with hydrochlorothiazide but not with fosinopril. Progression could also be avoided by associating pravastatin with hydrochlorothiazide.
[Comparison of the antihypertensive activity of fosinopril and irbesartan] [2002.11]
OBJECTIVE: To compare the antihypertensive effect of two daily single dose drugs acting on the renin-angiotensin axis by two different ways... CONCLUSIONS: Fosinopril and irbesartan seems to be equally effective to reduce DBP. Irbesartan might have higher effectiveness on systolic blood pressure. Irbesartan act more gradually than fosinopril and this may be useful to prevent from acute blood pressure falls.
Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. [2002.05]
This 12-week randomized, parallel-group, multicenter study compared fixed combinations of delapril (D) 30 mg plus indapamide (I) 2.5 mg and fosinopril (F) 20 mg plus hydrochlorothiazide (H) 12.5 mg in 171 adult patients with mild to moderate essential hypertension... In this study, the efficacy and safety of D + I were comparable to those of F + H in patients with mild to moderate essential hypertension.
Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. [1999.09]
Nonsteroidal antiinflammatory drugs (NSAID) are frequently reported to interfere with the blood pressure lowering actions of various antihypertensive medications. We studied 17 women with arthritis and hypertension who were receiving fosinopril and HCTZ, and administered sequentially in random order ibuprofen, sulindac, and nabumetone for 1 month each, with an intervening 2-week washout period between each treatment period...
Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction. [1999.05]
OBJECTIVE: To evaluate the pharmacokinetic interaction and bioequivalence of a combination formulation of the angiotensin-converting enzyme inhibitor fosinopril and the diuretic hydrochlorothiazide (HCTZ)... CONCLUSIONS: Fosinopril and HCTZ in a combination tablet display pharmacokinetic profiles similar to those achieved when either drug is administered alone or when coadministered in separate tablets. When used with HCTZ, the favorable pharmacokinetic feature of fosinopril, dual and compensatory pathways of renal and hepatic elimination, is preserved.
Clinical Trials Related to Fosinopril and Hydrochlorothiazide (Fosinopril / Hydrochlorothiazide)
Eplerenone, ACE Inhibition and Albuminuria [Recruiting]
The purpose of this study is to determine whether eplerenone is more effective than doubling
the dose of ACE inhibitor in reducing urinary protein (albumin) loss in diabetes mellitus
ACE Inhibition and Novel Cardiovascular Risk Factors [Completed]
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery [Not yet recruiting]
Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and
including the morning of an intermediate risk surgery will experience more intraoperative
hypotension than those who hold their chronic ACEI perioperatively.
Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and
including the morning of an intermediate risk surgery will experience better postoperative
control of hypertension than those who hold their chronic ACEI perioperatively.
Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and
including the morning of an intermediate risk surgery will experience less acute renal
failure than those who hold their chronic ACEI perioperatively.
Secondary research hypothesis #3: Patients with a preoperative systolic blood pressure less
than 110 mmHg who are continued on their chronicACEI therapy perioperatively will have a
significant decrease in blood pressure during anesthesia compared to those who have a
preoperative systolic blood pressure greater than 110 who are continued on their chronic
Secondary research hypothesis #4: Patients above the age of 64 who are continued on their
chronic ACEI therapy perioperatively will have a significant decrease in blood pressure
during anesthesia compared to those aged 64 or younger who are continued on their chronic
Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) [Recruiting]
A double blind randomised placebo controlled parallel trial of the effect of fosinopril, an
angiotensin converting enzyme inhibitor, on the quadriceps muscle in 80 COPD patients who
have quadriceps weakness. Patients will have a baseline assessment including measures of
quadriceps strength and endurance and a quadriceps biopsy. Patients with weakness will be
randomised to ACE inhibitor or placebo and re-assessed after three months of treatment.
The investigators aim to show that ACE-inhibition will alter the IGF-1/AKT/FoXO/atrogene
pathways involved in muscle wasting in COPD.
Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics [Recruiting]
It is controversial whether or not patients whose Renin Angiotensin System is blocked for
the treatment of hypertension suffer increased risk when undergoing surgery and anaesthesia.
The investigators wish to test the hypothesis: Blockade of the Renin Angiotensin System
causes altered dose response under general anaesthesia in a dose dependant manner. The
investigators wish to look for altered responses across the usual anaesthetic dosing range
as measured by blood pressure and heart responses.